Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
Sponsor
Children's Oncology Group (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01453465
Collaborator
National Cancer Institute (NCI) (NIH)
0
1
Study Details
Study Description
Brief Summary
This research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. Studying biomarkers of tissue samples from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
PRIMARY OBJECTIVES:
- To determine if there are molecular differences between rhabdoid tumor of the kidney (RTK) and the atypical teratoid rhabdoid tumor (ATRT).
OUTLINE:
Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
Study Design
Study Type:
Observational
Actual Enrollment
:
0 participants
Official Title:
Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT)
Actual Study Start Date
:
Nov 1, 2011
Actual Primary Completion Date
:
Dec 1, 2011
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Ancillary-Correlative (gene expression profile, miRNA profile) Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile. |
Other: Laboratory Biomarker Analysis
Correlative studies
|
Outcome Measures
Primary Outcome Measures
- Molecular differences between RTK and the ATRT [Up to 3 months]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Samples of RTK and ATRT provided by the Children?s Oncology Group (COG)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Childrens Oncology Group | Philadelphia | Pennsylvania | United States | 19104 |
Sponsors and Collaborators
- Children's Oncology Group
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Simone Sredni, Children's Oncology Group
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01453465
Other Study ID Numbers:
- ABTR12B1
- NCI-2011-03468
- CDR0000712872
- ABTR12B1
- COG-ABTR12B1
- ABTR12B1
- ABTR12B1
First Posted:
Oct 17, 2011
Last Update Posted:
Aug 7, 2018
Last Verified:
Oct 1, 2017